Evgen Pharma Share Discussion Threads

[amaretto1] 26/1/2021 07:31

65000 shares ?? I'm tempted to buy more that today alone :-/

[moneymunch] 25/1/2021 21:43

Anyways, regardless of who might have been selling and whatever the reason, let's hope the turn around in sentiment along with true and fair value will be with us soon....the delivery of lots of good and very positive newsflow in the coming weeks and months should do it. Gl :-)

[moneymunch] 25/1/2021 21:32

My point about Spreadex and Intertrader customer's selling their holdings was that perhaps then they would start betting short on the spread thereafter, which would also create downward pressure and suppress the share price ..which could explain the current share price performance....I realise there are many benefits for those who use these platforms, but I see little or no benefit for the stock in question . Gl :-)

[nobbygnome] 25/1/2021 21:17

>> MM

You didn't say they had sold their long position, you said they had gone short! The former is quite likely the latter is not....

WRT whether I have actually bought shares, well that is totally down to Spreadex whether they cover my long position. Rarely is there a corresponding trade when I buy on line. When I buy on the phone there usually is but not always. The same is true with IG where I only ever deal online and there is hardly ever a corresponding buy.

So for example back at the end of March there was a day when I realised DEMG was about to go mad for Covid reasons. The price was around 1p and I bought 5x100k positions with Spreadex over a five minute period. It is a thinly traded stock and there were no corresponding trades. The herd then arrived and it went above 2p for a brief period. I sold all 500k at various prices that day and banked £4800. There were no sales to correspond with the trades either so I presume Spreadex just paid £4800 into my account. I guess over a long period they gain more than they lose from this approach and £4800 is probably not that much to them in the greater scheme of things!

[moneymunch] 25/1/2021 21:03

Ps Nobby, one thing I'm curious about is the 65k of Evgen shares you're holding via Spreadex...have you actually bought 65k shares or just betting on the margin of 65k shares???

[moneymunch] 25/1/2021 20:55

Jeez, I don't give a toss who you're going to speak to, you haven't stopped going on about who has been selling shares and I've just highlighted that 2 spread betting companies were holding 6 % of Evgen end of November, which perhaps could account for the selling that would appear to have held back the share price

[nobbygnome] 25/1/2021 20:47

>> MM

You talk complete nonsense about Spreadex. I am going to speak to my account handler tomorrow and find out what % of EVG traders are actually short with Spreadex (it will be very low if not zero!) so I can stop that rubbish for good. No doubt you will say I am making it up but with his permission I will give you his email address so you can check yourself.

[amaretto1] 25/1/2021 20:25

Churning !

[moneymunch] 25/1/2021 19:55

Ps Intertrader and Spreadex both announced they were holding near enough 3% each end of November, and so a fair few shares if their clients were offloading and were now all betting short. ( their clients could be one investor or a handful of like minded cohorts and no doubt leveraged to the hilt ) . Gla :-)

[moneymunch] 25/1/2021 19:41

Most definitely Bumpa, and i'm still hoping that a high value deal will include a strategic investment, whereby a BIG player buys a chunk of the company for a shed load of cash, which would certainly explain why the share price remains somewhat surpressed.....unless the current performance is just down to the Spreadex effect...Gl :')

[nobbygnome] 25/1/2021 19:36

'A big player messing'; what for the last 3 months plus. How many shares have they got FFS!

[amaretto1] 25/1/2021 19:10

Or a big player ... messing !Let's not all get paranoid yet :-)

[nobbygnome] 25/1/2021 18:08

Well it seems to me someone knows more than we do. This company is clearly undervalued by a substantial amount yet someone keeps selling in large quantities. Doesn't smell right to me....

[bumpa33] 25/1/2021 17:49

mm - I think we could (finally) be off to the races pretty soon with all this recent news flow. I do still suspect a raise, but one that signals the shackles are off - when you have a story about to unfold, the snouts wanna get in on the action.


a “high value pre-clinical deal” would certainly be nice.

[amaretto1] 25/1/2021 17:48

C4XD is 100 percent higher !

[amaretto1] 25/1/2021 17:42

Not quite sure who's selling here...Manipulation of share price esp last week, Is a little disturbing ....It verged on unruly market, bad practise.I'll let you all know, what a close Nomad friend says, when he gets back to me.i continue to hold... and if nothing is a foot, may add a few more at this share price

[trollkiller555] 25/1/2021 17:41

why was that moderated?. People should be aware of his pump and dump

[amaretto1] 25/1/2021 17:36

Maybe third time lucky then ?

[moneymunch] 25/1/2021 16:23

Finnacap 21/1/21

Newsflow: Highly positive data for SFX-01 in pre-clinical models of glioma and glioblastoma have been generated through a collaboration with a prominent European university.

Fuller details are pending the publication in a peer-reviewed journal.

However, Evgen is particularly excited with the findings and with limited additional preclinical work, has indicated that SFX-01 could be ready to enter the clinic (Phase Ib/IIa) by the year-end.

Glioma is the most common type of brain tumour, developing in glial cells (supporting cells) in the brain or spinal cord. Different types of glioma are named after the types of glial cell and include Glioblastoma, which is an aggressive type of astrocytoma (forms in astrocyte cells).

Glioblastoma accounts for c.45% of cases with a median survival of 14 months and 5-year survival of c.5%. It is an orphan disease affecting 5 per 100,000 people.

We would expect SFX-01 to receive Orphan Drug Designation, Fast Track and potentially breakthrough status (in the US) as the treatment options are currently limited to surgery, radiotherapy and treatment with temozolomide.

Preclinical findings. Tumour shrinkage and significantly extended survival times were seen in standard pre-clinical models and then dosed with SFX-01, including more disease-relevant orthotopic models where glioma cells are implanted in brain tissue.

SFX-01 was also found also to substantially increase the therapeutic effect of radiotherapy in these models.


Implications: The data are sufficiently encouraging to warrant disclosure. Evgen retains all commercial rights to SFX-01 and will consider all options for further development.

It is quite conceivable that once limited additional preclinical work is completed a high-value preclinical deal could be struck, given the paucity of current treatment options and products in development for this indication.

[moneymunch] 25/1/2021 16:13

That's good to hear timbo, and so presumably when we have confirmation of Patent filing, the Scientific paper in preparation will be published, along with disclosure of the prominent European University....and very interesting that Huw refers to " another couple of collaborations" ....and so would be nice to think that one could have a commercial interest on proceedings....Gl ;-)

[bocker01] 25/1/2021 16:03

It was an excellent interview. Hew bursting with enthusiasm. Cannot help but feel that he’s the man to set up a deal stream... certainly he’ll have the contacts not just the energy. Quite a live wire!

[timbo003] 25/1/2021 15:49

Very intereresting to hear Huw state that there is a synergistic interaction between radiotherapy and SFX-01 in the glioblastoma model.

Any signs of synergism bodes well for securing some solid additional IP on the use of SFX-01 in combination with radio therapy for this indication, as Patent offices in most major juridistions regard synergy as an inventive step (i.e. not obvious) which is a prerequisite for patent grant.

[moneymunch] 25/1/2021 15:30

Hi Bumpa, just listened to Huw's latest interview again, and when talking about the glioblastoma, very exciting early data, he says that they are just working out now how to plan and more experiments and are " starting out on another couple of collaborations "......Gl ;-)

[moneymunch] 25/1/2021 12:38

Lol....yep, chance would be a fine thing...;-)))